Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). Background: There are no robust data published on the follow-up after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback